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INTRODUCTION
Cytomegalovirus (CMV) infection still remains a major
cause of morbidity and mortality in allogeneic stem cell trans-
plantation (SCT) recipients. While CMV infection of the cen-
tral nervous system (CNS) in acquired immune deficiency
syndrome patients has been reported relatively frequently, it
is an unusual presentation in allogeneic SCT recipients, but
fatal in all cases (1-4). Recently, unrelated cord blood or T-
cell depleted grafts have been increasingly used as an alter-
native source of hematopoietic stem cells. However, the use
of these grafts has been associated with an increased frequen-
cy of unusual CMV infections.
Here, we report a case of CMV ventriculoencephalitis after
unrelated double cord blood SCT with an alemtuzumab-con-
taining preparative regimen for Philadelphia-positive acute
lymphoblastic leukemia. The patient had recurrent CMV
DNAemia despite long-term treatment with antiviral agents
(foscarnet combined with ganciclovir) and anti-CMV im-
munoglobulin.
CASE REPORT
A 20-yr-old man underwent unrelated cord blood SCT
using two cord blood units to treat Philadelphia-positive
acute lymphoblastic leukemia. Each cord blood unit had 5/6
HLA compatibility. The patient was treated with total body
irradiation (1,200 cGy), fludarabine (150 mg/m2), cytarabine
(9 g/m2), and alemtuzumab (20 mg) as a preparative regimen.
Graft-versus-host disease prophylaxis was attempted by admin-
istering tacrolimus plus mizoribine. The patient was CMV-
seropositive at the time of transplantation. CMV serology test
was not performed in the cord blood. For prophylaxis of CMV
reactivation, acyclovir (10 mg/kg intravenously every 8 hr)
and anti-CMV immunoglobulin (150 mg/kg intravenously
biweekly) were given from day -7 until engraftment. The
patients achieved successful neutrophil and platelet engraft-
ment on day 27 and 51, respectively.
On day 33, CMV DNAemia was detected by real-time
quantitative polymerase chain reaction (RQ-PCR) as 3,775
copies/mL and the viral load increased steadily thereafter. The
patient was treated preemptively for CMV DNAemia with
foscarnet (60 mg/kg intravenously every 12 hr for 7 days, fol-
630
Seok Lee
1, Si-Hyun Kim
1, 
Su-Mi Choi
1, Dong-Gun Lee
1, 
Sung-Yong Kim
2, Jong-Wook Lee
1,
Woo-Sung Min
1, Wan-Shik Shin
1, 
and Chun-Choo Kim
1
Catholic Hematopoietic Stem Cell Transplantation
Center, College of Medicine
1, The Catholic University
of Korea, Seoul; Department of Hematology
2, Konkuk
University School of Medicine, Seoul, Korea
Address for Correspondence
Seok Lee, M.D.
Department of Hematology, Catholic HSCT Center,
The Catholic University of Korea, 62 Yeouido-dong,
Yeongdeungpo-gu, Seoul 150-713, Korea
Tel : +82.2-3779-1064, Fax : +82.2-780-3132
E-mail : leeseok@catholic.ac.kr
J Korean Med Sci 2010; 25: 630-3 ISSN 1011-8934
DOI: 10.3346/jkms.2010.25.4.630
Cytomegalovirus Ventriculoencephalitis after Unrelated Double Cord
Blood Stem Cell Transplantation with an Alemtuzumab-containing
Preparative Regimen for Philadelphia-positive Acute Lymphoblastic
Leukemia
Despite the prophylaxis and preemptive strategies using potent antiviral agents,
cytomegalovirus (CMV) remains a major infectious cause of morbidity and mortali-
ty in allogeneic stem cell transplantation (SCT) recipients. Delayed immune recon-
stitution after SCT, such as cord blood and T-cell depleted SCT with the use of alem-
tuzumab, has been associated with an increased frequency of CMV disease as well
as CMV reactivation. CMV disease involving central nervous system is an unusual
presentation in the setting of SCT. We report a case of CMV ventriculoencephalitis
after unrelated double cord blood SCT with an alemtuzumab-containing prepara-
tive regimen for Philadelphia-positive acute lymphoblastic leukemia.
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lowed by 90 mg/kg intravenously daily) from day 39 to day
93. During this period, CMV DNAemia decreased to low
levels (<500 copies/mL). Foscarnet had been chosen, instead
of ganciclovir, since it had less potential bone marrow toxic-
ity. Thirteen days after discontinuation of the foscarnet, CMV
retinitis developed with an increase in CMV DNA titer. The
foscarnet (90 mg/kg intravenously every 12 hr) and anti-CMV
immunoglobulin (150 mg/kg intravenously biweekly) were
re-administered. However, 7 days later, the CMV RQ-PCR
titers increased despite the treatment. Then we added gan-
ciclovir (5 mg/kg intravenously daily) on top of foscarnet (90
mg/kg intravenously daily). Clinically, the CMV retinitis im-
proved and the CMV DNAemia resolved 40 days after the
combination therapy.
On day 171, he was re-admitted complaining of progres-
sive weakness of all four extremities. An increased titer of
CMV RQ-PCR was noted again. The peripheral blood show-
ed pancytopenia without leukemic cells; a WBC count of
1,160/mL, hemoglobin of 6.9 g/dL, and a platelet count of
6,000/mL. Despite administration of foscarnet and anti-CMV
immunoglobulin, there was no improvement of CMV DNA-
emia. Rather, peripheral neuropathy was in progress and men-
tal status slowly deteriorated. He became inattentive and som-
nolent on day 185. A gadolinium-enhanced magnetic reso-
nance imaging of the brain (Fig. 1) showed multiple nodu-
larity with high signal intensities in the bilateral fronto-pari-
etal subcortical white matter, periventricular white matter,
and the basal ganglia in the T2-weighted and FLAIR images.
Diffuse high signal changes in the T2-weighted and FLAIR
images were also noted along the wall of the lateral ventricles,
which were enhanced with gadolinium on the T1-weighted
images. Lumbar puncture was performed on day 186; the
results showed a protein concentrate of 66.5 mg/dL, a glu-
cose concentrate of 62 mg/dL (serum glucose concentrate,
145 mg/dL), no white blood cells, and no red blood cells. The
microbiology of the cerebrospinal fluid (CSF) was negative
for bacteria, Mycobacterium species, and fungi. There was no
skin lesion that suggested a varicella zoster virus infection,
and the PCR analysis of the CSF for herpes simplex virus (type
1 & 2) and human herpes virus 6 were all negative. However,
the PCR analysis of the CSF was positive for CMV (Fig. 2).
Based on the typical radiologic findings, the positive PCR
for CMV from the CSF, and recurrent CMV DNAemia in
the peripheral blood in spite of long-term antiviral therapy,
a CMV ventriculoencephalitis had been diagnosed in the case.
Eventually the patient died of progressive deterioration of
CNS function on day 190. The clinical course and laborato-
ry data of the patient are summarized in Fig. 3.
DISCUSSION
Recently, posttransplant immune reconstitution after SCT
varies because of availability of alternative donor and variety
of preparative regimens and graft manipulations. The unre-
lated cord blood SCT and haploidentical transplantation them-
selves may be correlated with a high incidence of CMV reac-
tivation, when compared to matched sibling or unrelated SCT
(5, 6), as well as the use of antithymocyte globulin, fludara-
bine, and alemtuzumab (humanized monoclonal CD52 anti-
Fig. 1. Brain magnetic resonance images. The T1-weighted image (A) showed periventricular enhancement of subependymal regions (    ),
which indicated the ventriculoencephalitis. The FLAIR image (B) showed hyperintense lesions (*) in the hippocampus bilaterally, which
can be seen in diffuse encephalitis.
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body) as part of the preparative regimen (7-13). In particu-
lar, the combination of fludarabine and alemtuzumab might
cause a higher risk of CMV infection and earlier CMV infec-
tion following allogeneic SCT compared to other preparations
(8). Chakrabarti et al. (7) suggested that the patients receiv-
ing alemtuzumab, a total dose of 100 mg, had a higher inci-
dence of CMV infection; a lower dose of alemtuzumab might
be related with a reduced risk of CMV infection. Our patient
received a much lower dose of alemtuzumab, a total dose of
20 mg. However, he had a recurrent CMV reactivation and
finally developed CMV retinitis and ventriculoencephalitis.
A combination of intravenous foscarnet and ganciclovir has
been advocated for treatment of single drug-resistant CMV
disease (14, 15). We tried the combination regimen of foscar-
net and ganciclovir, expected to have synergistic effects, for
the treatment of CMV retinitis because of two reasons; 1) we
used the combination of fludarabine and alemtuzumab for
CBT preparation, which might have made the patient highly
susceptible to CMV reactivation; 2) CMV retinitis developed
after treatment with CMV DNAemia despite the recent pro-
longed treatment with foscarnet.
Clinically, the treatment failure of CMV disease with antivi-
ral drugs may be associated with antiviral resistance and/or
inadequate penetration of the drug into the infected tissue
(1, 3, 16, 17). The recurrent CMV DNAemia and progres-
sive CMV disease unresponsive to antiviral agents and anti-
CMV immunoglobulin for about 150 days, suggest antivi-
ral resistant-mutant CMV in the case. However, it is the lim-
itation of the current study that we could not perform drug
susceptibility analysis, CMV genotyping or phenotyping for
drug resistance-associated mutations, or measurement of the
drug levels in the plasma and CSF.
In summary, more aggressive prophylaxis as well as preemp-
tive therapy for CMV infection and more diligent monitor-
ing for progression to CMV diseases should be considered
for a certain proportion of SCT recipients with multiple risk
factors of delayed immune reconstitution.
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Fig. 3. The clinical course and RQ-PCR data.
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blood transplantation recipients as part of high-risk group at our
center.
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Tanaka-Taya, Osaka University Graduate School of Medicine,
Osaka, Japan). Lanes: M, 100 bp DNA ladder; 1, negative con-
trol; 2, CMV; 3, HHV-6; 4, CSF of the patient.
421 bp
M1 2 34
230 bpCytomegalovirus Ventriculoencephalitis after Cord Blood Stem Cell Transplantation 633
7. Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Peggs K,
O’Gorman P, Chakraverty R, Marshall T, Osman H, Mahendra P,
Craddock C, Waldmann H, Hale G, Fegan CD, Yong K, Goldstone
AH, Linch DC, Milligan DW. High incidence of cytomegalovirus
infection after nonmyeloablative stem cell transplantation: potential
role of Campath-1H in delaying immune reconstitution. Blood 2002;
99: 4357-63.
8. Bainton RD, Byrne JL, Davy BJ, Russell NH. CMV infection follow-
ing nonmyeloablative allogeneic stem cell transplantation using Cam-
path. Blood 2002; 100: 3843-4.
9. Mohty M, Faucher C, Vey N, Stoppa AM, Viret F, Chabbert I, Cha-
bannon C, Bouabdallah R, Ladaique P, Collet L, Zandotti C, Maran-
inchi D, Blaise D. High rate of secondary viral and bacterial infec-
tions in patients undergoing allogeneic bone marrow mini-transplan-
tation. Bone Marrow Transplant 2000; 26: 251-5.
10. Redy V, Pollock BH, Sharda S, Hopkins J, Weeks F, Manion K,
Roque D, Leather HL, Finiewicz KJ, Khan SA, Mehta P, Moreb JS,
Wingard JR. GVHD and CMV antigenemia after allogeneic periph-
eral blood stem cell transplantation: comparison between myeloab-
lative and nonmyeloablative (mini) conditioning regimens. Blood
2000; 96: 191a.
11. Junghanss C, Boeckh M, Carter R, Sandmaier BM, Maloney D,
Chauncey T, McSweeney PA, Corey L, Storb R. Incidence of her-
pesvirus infections following nonmyeloablative allogeneic stem cell
transplantation. Blood 2000; 96: 188a.
12. Schilling PJ, Vadhan-Raj S. Concurrent cytomegalovirus and pneu-
mocystis pneumonia after fludarabine therapy for chronic lympho-
cytic leukemia. N Engl J Med 1990; 323: 833-4.
13. Martin SI, Marty FM, Fiumara K, Treon SP, Gribben JG, Baden LR.
Infectious complications associated with alemtuzumab use for lym-
phoproliferative disorders. Clin Infect Dis 2006; 43: 16-24.
14. Mylonakis E, Kallas WM, Fishman JA. Combination antiviral ther-
apy for ganciclovir-resistant cytomegalovirus infection in solid-organ
transplant recipients. Clin Infect Dis 2002; 34: 1337-41.
15. Anduze-Faris BM, Fillet AM, Gozlan J, Lancar R, Boukli N, Gas-
nault J, Caumes E, Livartowsky J, Matheron S, Leport C, Salmon
D, Costagliola D, Katlama C. Induction and maintenance therapy
of cytomegalovirus central nervous system infection in HIV-infected
patients. AIDS 2000; 14: 517-24.
16. Fletcher C, Sawchuk R, Chinnock B, de Miranda P, Balfour HH Jr.
Human pharmacokinetics of the antiviral drug DHPG. Clin Phar-
macol Ther 1986; 40: 281-6.
17. Wagstaff AJ, Bryson HM. Foscarnet. A reappraisal of its antiviral
activity, pharmacokinetic properties and therapeutic use in immuno-
compromised patients with viral infections. Drugs 1994; 48: 199-226.
18. Park ST, Kim SH, Lee DG, Choi JH, Shin WS, Kim TG, Paik SY,
Kim CC. Detection of lymphotropic herpesviruses by multiplex poly-
merase chain reaction. J Microbiol 2001; 39: 226-8.